Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 51
Filter
1.
Article in Chinese | WPRIM | ID: wpr-907402

ABSTRACT

Objective:To detect the expression of replication factor C4(RFC4) in pancreatic ductal adeno-carcinoma, and to explore the clinical prognosis of RFC4 and pancreatic ductal adenocarcinoma. To explore the possibility of RFC4 as a potential biomarker for pancreatic ductal adenocarcinoma.Methods:The mRNA level of RFC4 in pancreatic ductal adenocarcinoma and normal tissues adjacent to the cancer was analyzed by bioinformatics methods, and the relationship between its expression and the survival rate of patients with pancreatic ductal adenocarcinoma was analyzed. The clinicopathological data of 76 patients with pancreatic ductal adenocarcinoma who underwent surgical treatment were retrospectively analyzed. Immunohistochemical method was used to detect the expression level of RFC4 protein in pancreatic ductal adenocarcinoma tissue and normal tissues adjacent to the cancer, and to analyze its relationship with clinicopathological characteristics of patients with pancreatic ductal adenocarcinoma.Results:The results of bioinformatics analysis showed that RFC4 mRNA was significantly highly expressed in pancreatic ductal adenocarcinoma tissue, and was significantly correlated with the overall survival rate ( P=0.046) and disease-free survival rate ( P=0.042) of the patients. Immunohistochemical results showed that the expression of RFC4 in pancreatic ductal adenocarcinoma tissue was significantly higher than that in normal tissues adjacent to the cancer. The high expression of RFC4 in pancreatic ductal adenocarcinoma tissue was related to tumor size ( P=0.043), but not related to age, gender, and tumor grade (all P>0.05). Conclusions:RFC4 is highly expressed in pancreatic ductal adenocarcinoma tissues and indicates a poor prognosis, and its expression level is related to the tumor stage of pancreatic ductal adenocarcinoma. RFC4 may serve as a new prognostic predictor for pancreatic ductal adenocarcinoma.

2.
Rev. argent. mastología ; 38(138): 35-44, jul 2019. graf
Article in Spanish | LILACS | ID: biblio-1116799

ABSTRACT

Objetivos Se analizaron 331 pacientes con tumores de mama de entre 0,1 y 1 cm tratados en la Unidad de Mastologia Clínica Breast, Hospital Italiano de La Plata, en el período de tiempo comprendido entre 2012 y 2017. Se estudiaron factores pronósticos (tamaño tumoral, edad, ivl, grado histológico, tipo y subtipo tumoral y Ki67) y su relación con el compromiso ganglionar, el cual se encontró presente en 42 casos (12,98%). Resultados El subtipo tumoral con mayor afectación axilar fue el tn seguido por los Luminal B. La edad y tamaño tumoral no arrojaron datos relevantes. La ivl y el Ki67 fueron las variables más significativas en relación con el compromiso axilar. Conclusiones Pudimos concluir que nos hallamos dentro de los valores estándares publicados tanto nacional como internacionalmente


Objective We analyzed 331 patients with breast tumors between 0.1 and 1 cm treated in the Breast-Italian Hospital La Plata Clinical Mastology Unit, in the period between 2012 and 2017. We studied prognostic factors (tumor size, age, ivl, histological grade, tumor type and subtype and Ki67) and its relationship with lymph node involvement, which was present in 42 cases (12.98%). Results The tumor subtype with the most axillary involvement was tn followed by Luminal B. Age and tumor size did not yield relevant data. The ivl and the Ki67 were the most significant variables in relation to the axillary commitment. Conclusions We were able to conclude that we are within the standard values published both nationally and internationally


Subject(s)
Prognosis , Breast Neoplasms , Lymph Nodes , Neoplasms
3.
Article in Chinese | WPRIM | ID: wpr-844029

ABSTRACT

Objective: To compare the feasibility of automated breast volume scanner automated breast ultrasound system (ABUS) and the traditional ultrasound (US) in measuring breast cancer size so as to evaluate their value in predicting breast cancer T staging. Methods: We retrospectively recruited 60 women with breast cancer who had received US and ABUS. The maximal tumor diameter was measured as tumor size. Based on the actual postoperative tumor size in pathology, Bland-Altman analysis and intraclass correlation coefficient (ICC) were used to compare the values measured by US and ABUS. Then we made a preliminary study of the accuracy of US and ABUS in predicting breast cancer T staging. Results: The best absolute agreement was shown between US and ABUS in measuring tumor size. Moreover, ABUS showed better agreement with histology than US [average difference (-1.09±3.61)mm vs. (-1.57±4.99)mm] with a higher ICC (0.93 vs. 0.86), especially for tumors which were more than 2 cm. In addition, both US and ABUS could predict breast cancer T staging relatively accurately (82.1% vs. 87.5%). Conclusion: Both US and ABUS showed good agreement with pathology in measuring tumor size. ABUS even outperformed US in assessing tumor size for tumors beyond 2 cm. Therefore, ABUS can be considered as an alternative to US in T staging of breast cancer.

4.
Article in English | WPRIM | ID: wpr-719331

ABSTRACT

PURPOSE: The purpose of this study was to investigate the non-inferiority of omitting radiotherapy (RT) after breast-conserving surgery (BCS) for hormone receptor (HR)‒positive T1N0 breast cancer in elderly women. MATERIALS AND METHODS: From 2004 to 2014, HR-positive T1N0 breast cancer patients aged 50 years or older and receiving BCS were retrieved from the Surveillance, Epidemiology, and End RESULTS: 18 database. After propensity score matching between the no-RT and RT groups, univariate and multivariate analyses were performed. Identified prognostic factors were used to stratify the risk groups. In each risk group, 10-year cancer-specific survival (CSS) rates were compared between the no-RT and RT groups. RESULTS: After propensity score matching, the numbers of patients in the no-RT and RT groups were both 18,586. For patients who satisfied both a tumor size of 1-10 mm and a tumor grade of 1-2, omitting RT did not decrease the CSS rate at any age group, ranging from ≥ 50 to ≥ 85 years; for patients aged ≥ 50 years, the 10-year CSS rates in the no-RT and RT groups were 97.2% and 96.8%, respectively (adjusted hazard ratio, 0.862; p=0.312). However, for patients with a tumor size of 11-20 mm or tumor grade of 3-4, RT significantly increased the CSS rate irrespective of age. CONCLUSION: RT after BCS for HR-positive T1N0 breast cancer in elderly women might be omitted without causing a decrease in the CSS rate, but only in patients who satisfy both a small tumor size (≤ 10 mm) and low tumor grade (1-2).


Subject(s)
Aged , Breast Neoplasms , Breast , Epidemiology , Female , Humans , Mastectomy, Segmental , Multivariate Analysis , Propensity Score , Radiotherapy , Radiotherapy, Adjuvant , Receptors, Estrogen , Receptors, Progesterone
5.
Medicina (B.Aires) ; 78(4): 234-242, ago. 2018. graf, map, tab
Article in Spanish | LILACS | ID: biblio-954989

ABSTRACT

El cáncer cérvico-uterino, fiel indicador de inequidad social, sigue siendo un grave problema de salud pública en la República Argentina. Se suele afirmar que su frecuencia en mujeres jóvenes es baja y que las más expuestas son aquellas mayores de 35 años. Sin embargo, como ginecólogos oncólogos, con frecuencia acompañamos a morir a mujeres jóvenes que no han tenido acceso a tamizaje ni a tratamiento oportuno y adecuado del cáncer invasor. Esto ha motivado el presente análisis de frecuencia y supervivencia del cáncer cérvico-uterino en el contexto demográfico de las mujeres asistidas en el hospital de referencia en cáncer ginecológico de Buenos Aires. De los 748 casos analizados retrospectivamente (2007-2011), el 84.0% (n = 627) residía en el Área Metropolitana de Buenos Aires y el 76.9% (n = 576) fue admitido en estadios loco-regionalmente avanzados. El 53.6% (n = 401) presentó un diámetro tumoral > 4 cm y el 24.2% (n = 181) > 6 cm. Las tasas más bajas de supervivencia se observaron en tumores > 6 cm y en el subgrupo etario < 35 años. Tanto el tamaño tumoral como la edad conservaron su valor pronóstico tras ser ajustados en el análisis multivariado. En el subgrupo < 35 años, el 48% (n = 70) murió durante los 5 años siguientes al diagnóstico y la probabilidad de sobrevivir otros 5 años fue < 50%. Estos resultados representan una alerta sanitaria sobre la situación de mujeres jóvenes con cáncer cérvico-uterino en el Área Metropolitana de Buenos Aires, la cual concentra casi un tercio de la población del país.


he cervical cancer, which is a reliable indicator of social inequality, remains a major public health issue in Argentina. It is generally accepted that its frequency among young women is low, being the most exposed those over 35 years old. Nevertheless, as gynecologic oncologists, we have been accompanying young patients to their death, mostly women with neither access to screening strategies nor timely or suitable treatment. Such a situation motivated the present analysis of our data on frequency, survival, and demography of cervical cancer collected at the referral cancer hospital of Buenos Aires City. Of 748 cases retrospectively assessed (2007-2011), 84.0% (n = 627) resided in the Metropolitan Area of Buenos Aires; 76.9% (n = 576) were admitted at a locoregionally advanced stage. Regarding tumor size, 53.6% (n = 401) had tumors > 4 cm diameter and 24.2% (n = 181) > 6 cm. The lowest rates of disease-free survival and cause-specific survival were observed for tumor sizes > 6 cm and the age subgroup < 35 years old. Both tumor size and age retained their prognostic value after multivariate analysis adjustment. When focusing in patients under 35 years old, 48% (n = 70) died within 5 years following diagnosis and their probability of surviving 5 years more was < 50%. These figures raise a public health alert on young women with cervical cancer living in the Metropolitan Area of Buenos Aires, which concentrates almost one third of the country population.


Subject(s)
Humans , Female , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Uterine Cervical Neoplasms/mortality , Argentina/epidemiology , Urban Population , Survival Analysis , Retrospective Studies , Age Factors , Neoplasm Staging
6.
Article in English | WPRIM | ID: wpr-715131

ABSTRACT

OBJECTIVE: To test whether the impact of thyroid-nodule size on the malignancy risk differs according to the ultrasonography (US) patterns of nodules. MATERIALS AND METHODS: This study is a post hoc analysis using data from the Thyroid Imaging Reporting and Data System (TIRADS) multicenter retrospective study which included 2000 consecutive thyroid nodules (≥ 1 cm) with final diagnoses. A total of 2000 consecutive thyroid nodules from 1802 patients (1387 women and 613 men; mean age, 51.2 ± 12.2 years) were enrolled in this study. The malignancy risk of the nodules was assessed according to the nodule size and US patterns (Korean-TIRADS). RESULTS: Overall, the malignancy risk did not increase as nodules enlarged. In high-suspicion nodules, the malignancy rate had no association with nodule size (p = 0.467), whereas in intermediate- or low-suspicion nodules there was a trend toward an increasing malignancy risk as the nodule size increased (p = 0.004 and 0.002, respectively). The malignancy rate of large nodules (≥ 3 cm) was higher than that of small nodules (< 3 cm) in intermediate-suspicion nodules (40.3% vs. 22.6%, respectively; p = 0.001) and low-suspicion nodules (11.3% vs. 7.0%, respectively; p = 0.035). There was a trend toward a decreasing risk and proportion of papillary carcinoma and an increasing risk and proportion of follicular carcinoma or other malignant tumors as nodule size increased (p < 0.001, respectively). CONCLUSION: The impact of nodule size on the malignancy risk differed according to the US pattern. A large nodule size (≥ 3 cm) showed a higher malignancy risk than smaller nodules in intermediate- and low-suspicion nodules.


Subject(s)
Carcinoma, Papillary , Diagnosis , Female , Humans , Information Systems , Male , Retrospective Studies , Thyroid Gland , Thyroid Nodule , Ultrasonography
7.
Arch. endocrinol. metab. (Online) ; 61(5): 464-469, Sept.-Oct. 2017. tab, graf
Article in English | LILACS | ID: biblio-887592

ABSTRACT

ABSTRACT Objective Ghrelin plays a role in several processes of cancer progression, and numerous cancer types express ghrelin and its receptor. We aimed to investigate serum levels of ghrelin in patients with papillary thyroid carcinoma (PTC) and its association with the prognostic factors in PTC. Materials and methods We enrolled 54 patients with thyroid cancer (7 male, 47 female) and 24 healthy controls (6 male, 18 female) in the study. We compared demographic, anthropometric, and biochemical data, and serum ghrelin levels between the groups. Serum ghrelin levels were measured using as enzyme-linked immunosorbent assay. Results Ghrelin levels were similar between the groups, but plasma ghrelin levels were significantly higher in tumors larger than 1 cm diameter compared with papillary microcarcinomas. Serum ghrelin levels also correlated with tumor size (r = 0.499; p < 0.001). Body mass index, thyroid-stimulating hormone, and HOMA-IR levels were similar between the groups. There were no statistically significant differences regarding average age and other prognostic parameters including lymph node invasion, capsule invasion, multifocality and surgical border invasion between patients with microcarcinoma and tumors larger than 1 cm. Conclusion In our study, no significant difference in serum ghrelin levels was determined between patients with papillary thyroid cancer and healthy controls however, serum ghrelin levels were higher in tumors larger than 1 cm compared to in those with thyroid papillary microcarcinoma.


Subject(s)
Humans , Male , Female , Adult , Thyroid Neoplasms/blood , Carcinoma, Papillary/blood , Ghrelin/blood , Prognosis , Enzyme-Linked Immunosorbent Assay , Thyroid Neoplasms/pathology , Carcinoma, Papillary/pathology , Biomarkers, Tumor/blood , Case-Control Studies , Tumor Burden , Thyroid Cancer, Papillary , Neoplasm Invasiveness , Neoplasm Staging
8.
Article in Chinese | WPRIM | ID: wpr-514959

ABSTRACT

OBJECTIVE The aim of the study was to evaluated the difference and consistency in tumor size measured by sonographic and pathological examination in papillary thyroid carcinoma(PTC).METHODS A total of 114 patients with PTC, including 122 malignant nodules, was collected from Hangzhou First People's Hospital between Jun 2012 and Jun 2014. The tumor sizes were measured by preoperative sonographic and postoperative pathologic evaluation. Pearson correlation analysis, paired t-test, and Bland-Altman plot were used to evaluate the correlation and consistency in tumor size measured by the two methods.RESULTS Pearson correlation analysis showed that the largest tumor size measured by sonography were positively correlated with pathologic size (r=0.957, P=0.000). Paired t-test showed that there were statistically difference between sonographic size and pathological size (8.24±5.06) mmvs (7.79±4.75) mm,P=0.001. The absolute difference value of the largest tumor size measured by the two methods was from zero to 6.5 mm, with the average of (1.03±1.14) mm. Bland-Altman analysis showed that the limits of agreement (LoA) of difference was from -2.41 mm to 3.33 mm, with the 95% confidence interval from -2.87 mm to 3.78 mm.Within the limit of the consistency, the maximum moduli was 2.9 mm.CONCLUSION There is a significant discrepancy between the preoperative sonographic and the pathologic size of the papillary thyroid carcinoma, which should be taken into account in clinical practice.

9.
Article in English | WPRIM | ID: wpr-68334

ABSTRACT

In oncology trials, patients are withdrawn from study at the time when progressive disease (PD) is diagnosed, which is defined as 20% increase of tumor size from the minimum. Such informative censoring can lead to biased parameter estimates when nonlinear mixed effects models are fitted using NONMEM. In this work, we investigated how empirical Bayes estimates (EBE) could be exploited to impute missing tumor size observations and partially correct biases in the parameter estimates. 50 simulated datasets, each consisting of 100 patients, were generated based on the published model. From the simulated dataset, censoring due to PD diagnosis has been implemented. Using the post-hoc EBEs acquired from fitting the censored datasets using NONMEM, imputed values were generated from the tumor size model. Model fitting was carried out using censored and imputed datasets. Parameter estimates using both datasets were compared with true values. Tumor growth rate and cell kill rate were approximately 28% and 16% underestimated when fitted using the censored dataset, respectively. With the imputed datasets, relative biases of tumor growth rate and cell kill rate decreased to about 6% and 0%, respectively. Our work demonstrates that using EBEs acquired from fitting the model to the censored dataset and imputing the unknown tumor size observations with individual predictions beyond the PD time point is a viable option to solve the bias associated with structural parameter estimates. This approach, however, would not be helpful in getting better estimates of variance parameters.


Subject(s)
Bays , Bias , Dataset , Diagnosis , Humans , Methods
10.
Article in English | WPRIM | ID: wpr-128616

ABSTRACT

BACKGROUND/AIMS: The predictive role of contrast-enhanced ultrasonography (CEUS) before performing transarterial chemoembolization (TACE) has not been determined. We assessed the possible predictive factors of CEUS for the response to TACE. METHODS: Seventeen patients with 18 hepatocellular carcinoma (HCC) underwent TACE. All of the tumors were studied with CEUS before TACE using a second-generation ultrasound contrast agent (SonoVue(R), Bracco, Milan, Italy). The tumor response to TACE was classified with a score between 1 and 4 according to the remaining enhancing-tumor percentage based on modified response evaluation criteria in solid tumors (mRECIST): 1, enhancing tumor or =75%). A score of 1 was defined as a "good response" to TACE. The predictive factors for the response to TACE were evaluated during CEUS based on the maximum tumor diameter, initial arterial enhancing time, arterial enhancing duration, intensity of arterial enhancement, presence of a hypoenhanced pattern, and the feeding artery to the tumor. RESULTS: The median tumor size was 3.1 cm. The distribution of tumor response scores after TACE in all tumors was as follows: 1, n=11; 2, n=4; 3, n=2; and 4, n=1. Fifteen tumors showed feeding arteries. The presence of a feeding artery and the tumor size (< or =5 cm) were the predictive factors for a good response (P=0.043 and P=0.047, respectively). CONCLUSIONS: The presence of a feeding artery and a tumor size of less than 5 cm were the predictive factors for a good response of HCC to TACE on CEUS.


Subject(s)
Adult , Aged , Aged, 80 and over , Antibiotics, Antineoplastic/administration & dosage , Carcinoma, Hepatocellular/pathology , Chemoembolization, Therapeutic , Contrast Media/chemistry , Doxorubicin/administration & dosage , Female , Humans , Liver Neoplasms/pathology , Male , Microspheres , Middle Aged , Tomography, X-Ray Computed , Treatment Outcome
11.
Journal of Practical Radiology ; (12): 1443-1446, 2015.
Article in Chinese | WPRIM | ID: wpr-479040

ABSTRACT

Objective To compare the accuracy of mammography and ultrasonography in evaluating the tumor size of breast ductal carcinoma in situ before operation.Methods Eighty-seven patients with breast ductal carcinoma in situ confirmed by surgery pathology were retrospectively analyzed.All of the mammography and ultrasonography data were well-documented.The maximum diameter of the tumor was measured by mammography,ultrasonography and pathology,respectively.It was considered concordant if the difference between the imaging size and pathologic size was less than 0.5 cm.Pearson correlation analysis was used to determine the relation of imaging size with pathologic size.Results The range of the maximum diameter of the tumors measured by pathology,mammography and ultrasonography was 0.4-7.0 cm,0.8-6.9 cm and 0.5-4.8 cm,respectively.The mean value was (2.4±1.3)cm,(2.6±1.2)cm and (2.3±1.0)cm,respectively.The coefficient correlation between mammographic and pathologic size was 0.724,and between ultra-sonographic and pathologic size was 0.532.Conclusion Mammography is more accurate than ultrasonography in size assessment of breast ductal carcinoma in situ.

12.
Article in Chinese | WPRIM | ID: wpr-463606

ABSTRACT

Objective To investigate whether there are differences of the characteristics of the contrast‐enhanced ultrasound among breast cancer vary in size .Methods The contrast‐enhanced ultrasound perfusion mode were retrospectively analyzed in 113 cases of breast cancer patients with 119 lesions .They were divided into two groups according to the maximum diameter of the lesion based on ultrasound measured ,one group (≤2 0. cm ) 47 cases ,the other group (> 2 0. cm ) 72 cases .The characteristics and mode of contrast‐enhanced ultrasound of the lesion were analyzed ,including whether is greater than the two‐dimensional ultrasound in enhanced range ,enhanced strength ,the distribution of the contrast agent ,contrast agent perfusion sequence in lesions ,contrast mode ,and the existence of perforator vessels and perfusion defects .Results Enhanced strength ,the existence of perforator vessels and perfusion defects associated with the size of the lesions .The breast cancer lesions more than 20 cm were apt to higher enhance strength ,the presence of perfusion defects ,perforator vessels ( P 0 0.5) .Regardless of breast lesions size ,the enhanced range tended to larger than two‐dimensional ultrasound range ,and contrast‐enhanced ultrasound present inhomogeneous ,centrality and integrity filling and perfusion mode of quickly rising and falling .Conclusions Within breast tumor angiogenesis is gradual .With the increase of tumor volume ,more significant vascular heterogeneity ,breast cancer lesion are more prone to uneven high perfusion ,accompanied by perfusion defects and perforating vessels ,but the main sign of differentiating benign and malignant showed consistency between different sized lumps in breast cancer ,which included whether or not contrast mode and enhanced range greater than two‐dimensional ultrasonic range .

13.
Br J Med Med Res ; 2015; 9(2): 1-7
Article in English | IMSEAR | ID: sea-180840

ABSTRACT

Aim: The present study was undertaken with the purpose to assess the correlation between the presence of lymph node metastases and the size of tumor and the thickness of the tumor mass. Methods: The study included 80 consecutive cases of oral squamous cell carcinoma, who underwent radical neck dissection. The various level of lymph nodes in these cases were checked for metastases, which was then correlated with the size of tumor and the thickness of the tumor. Results: In this study it was revealed that there is a statistically non-significant (p = 0.3204) correlation between size of the tumor and regional cervical lymph node metastases, but a significant correlation (p = 0.0148) between thickness of the tumor and regional cervical lymph node metastases was observed. Conclusion: Thus we conclude that the tumor thickness was more in cases with skip metastasis than in cases without skip metastasis and tumors greater than 10mm in thickness have more chances of regional metastases.

14.
Rev. chil. urol ; 78(4): 51-53, ago. 2013.
Article in Spanish | LILACS | ID: lil-774917

ABSTRACT

El tratamiento de las masas renales sólidas menores de cuatro centímetros constituye un tema de debate. La “vigilancia activa” se ha propuesto como alternativa para su manejo, sin embargo, estudios publicados recientemente, señalan que un porcentaje no despreciable de estos tumores resultan ser malignos, e incluso en un 6 por ciento de los casos pueden producir metástasis. El objetivo del presente estudio consiste en determinar el riesgo de malignidad en masas renales sólidas menores de cuatro centímetros en un grupo de pacientes sometidos a Nefrectomía Parcial Laparoscópica (NPL). Estudio retrospectivo de pacientes sometidos a NPL. Se seleccionaron aquellos que presentaron lesiones renales sólidas menores a 4 cm informadas por TAC y/o RMN. Se crearon intervalos de tamaño (<2 cm, 2-2.9 cm, 3-4 cm). Se realizó un análisis univariado para determinar el riesgo de malignidad de acuerdo al tamaño del tumor, estableciendo el Odds Ratio correspondiente y el intervalo de confianza (95 por ciento). Los datos obtenidos fueron analizados mediante el programa SPSS v17. Se consideró como significativo un p< 0.05. Entre los años 2000 y 2012 se efectuaron 135 nefrectomías parciales laparoscópicas por la presencia de una masa renal sólida. Noventa y dos casos presentaron lesiones menores a cuatro centímetros, los que fueron incluidos en este estudio. Del total de tumores el 9.8% resultó ser benigno en el estudio histopatológico definitivo. No existieron diferencias significativas (p=0,67) con respecto a la media del tamaño (2,2 y 2,57 cm respectivamente) entre los tumores benignos y malignos. El porcentaje de tumores malignos aumentó significativamente (p = 0,025) en las masas mayores de 2 cm, al compararlo con aquellas de menor tamaño (69 por ciento v/s 86.7 por ciento). Mediante el análisis univariado se estableció que el riesgo de malignidad se incrementa 4.9 veces (p=0.027) en aquellas masas renales sólidas mayores de 2 cm...


The treatment of solid renal masses less than four centimeters (cm) is a subject of debate. Active surveillance has been proposed as a management option, however, recently published studies indicate that, in a substantial proportion, these tumors are malignant; and even at 6 percent of the cases can produce metastases. The aim of this study was to determine the malignancy risk in solid renal masses less than four cm in a group of patients undergoing laparoscopic partial nephrectomy (LPN).A retrospective study of patients undergoing LPN was performed. We selected those who had solid renal lesions smaller than 4 cm reported by CT and/or MRI. Size ranges were set (<2 cm, 2-2.9 cm, 3-4 cm). Univariate analysis was performed to determine the risk of malignancy according to tumor size, obtaining the corresponding odds ratio and confidence interval (95 percent). Data were analyzed using SPSS v17. P-value < 0.05 was considered stadistically significant. RESULTS: One hundred and thirty five laparoscopic partial nephrectomies were performed due to a solid renal mass between 2000 and 2012. Of them, ninety-two cases had a lesion less than four cm, which were included in this study. From the total of tumors, 9.8 por ciento were proved benign on final histopathology. No significant difference was found between benign and malignant tumors when mean sizes were compared (2.2 and 2.57 cm, respectively, p =0.67). The percentage of malignant tumors was significantly higher in masses larger than 2 cm, compared with those of smaller size (86.7 percent v/s 69 percent respectively, p=0.025). Univariate analysis established that the malignancy risk is increased 4.9 times in solid renal masses larger than 2 cm (p = 0.027). Our study shows that although the risk of cancer increases significantly in renal masses from the 2 cm there is a considerable percentage of malignancy in masses below this size.


Subject(s)
Humans , Laparoscopy , Nephrectomy/methods , Kidney Neoplasms/pathology , Precancerous Conditions/pathology , Risk Assessment , Tumor Burden
15.
Indian J Cancer ; 2013 July-Sept; 50(3): 189-194
Article in English | IMSEAR | ID: sea-148647

ABSTRACT

CONTEXT: Vimentin is a mesenchymal marker, known to express in some epithelial carcinomas. AIMS: 1. To find out the expression of vimentin in infiltrating ductal carcinoma of breast (not otherwise specified), 2. To find out the correlation between expression of vimentin and prognostic markers such as tumor size, tumor grade, lymph node status, proliferation index (measured by Ki 67), and Nottingham prognostic index (NPI). MATERIALS AND METHODS: Study was done at Department of Pathology; 50 cases of infiltrating ductal carcinoma (NOS) were studied for tumor grade; immunohistochemistry was done using antibodies against vimentin and Ki 67. Percentages of positive cells were documented. An immunoscore was also calculated for vimentin. Vimentin expression was correlated with tumor size, lymph node status, Nottingham prognostic index, and Ki 67. Statistical analysis used: statistical correlation was done using Pearson’s chi-square test. A P value less than 0.01 was considered significant. RESULTS: Vimentin expression was seen in 18% of cases. Its expression correlated with high tumor grade and high growth fraction (P value < 0.01). It did not correlate with lymph node status, tumor size, and NPI. CONCLUSIONS: Increased vimentin expression is associated with bad prognostic factors. Immunohistochemistry with vimentin may be helpful in knowing the prognosis in cases of infiltrating ductal carcinoma of breast (NOS).


Subject(s)
Adult , Aged , Aged, 80 and over , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/pathology , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Ki-67 Antigen/biosynthesis , Middle Aged , Neoplasm Grading , Prognosis , Retrospective Studies , Biomarkers, Tumor/analysis , Vimentin/analysis , Vimentin/biosynthesis
16.
Gut and Liver ; : 642-647, 2013.
Article in English | WPRIM | ID: wpr-162816

ABSTRACT

BACKGROUND/AIMS: The accurate preoperative prediction of the risk of malignancy of gastrointestinal stromal tumors (GISTs) is difficult. The aim of this study was to determine whether tumor size and endoscopic ultrasonography (EUS) features can preoperatively predict the risk of malignancy of medium-sized gastric GISTs. METHODS: Surgically resected, 2 to 5 cm gastric GIST patients were enrolled and retrospectively reviewed. EUS features, such as heterogeneity, hyperechoic foci, calcification, cystic change, hypoechoic foci, lobulation, and ulceration, were evaluated. Tumors were grouped in 1 cm intervals. The correlations of tumor size or EUS features with the risk of malignancy were evaluated. RESULTS: A total of 75 patients were enrolled. The mean tumor size was 3.43+/-0.92 cm. Regarding the risk of malignancy, 51 tumors (68%) had a very low risk, and 24 tumors (32%) had a moderate risk. When the tumors were divided into three groups in 1 cm intervals, the proportions of tumors with a moderate risk were not different between the groups. The preoperative EUS features also did not differ between the very low risk and the moderate risk groups. CONCLUSIONS: Tumor size and EUS features cannot be used to preoperatively predict the risk of malignancy of medium-sized gastric GISTs. A preoperative diagnostic modality for predicting risk of malignancy is necessary to prevent the overtreatment of GISTs with a low risk of malignancy.


Subject(s)
Aged , Endosonography , Female , Gastrointestinal Stromal Tumors/pathology , Humans , Male , Middle Aged , Mitotic Index , Predictive Value of Tests , Preoperative Period , Retrospective Studies , Risk Assessment , Stomach Neoplasms/pathology , Tumor Burden
17.
Article in English | WPRIM | ID: wpr-90259

ABSTRACT

BACKGROUND: Tumor-associated macrophages (TAMs) play a tumorigenic role related to advanced staging and poor prognosis in many human cancers including thyroid cancers. Yet, a functional role of TAMs in papillary thyroid carcinoma (PTC) has not been established. The aim of this study was to investigate TAM expression in human PTC with lymph node (LN) metastasis. METHODS: Thirty-six patients who underwent surgery after being diagnosed with PTC with LN metastasis were included. Primary tumor tissues were immunohistochemically stained with an anti-CD68 antibody and clinical characteristics according to TAM density were evaluated. RESULTS: The TAM densities (CD68+ cells) varied from 5% to 70%, in all tumor areas, while few cells were stained in adjacent normal tissues. TAMs were identified as CD68+ cells with thin, elongated cytoplasmic extensions that formed a canopy structure over tumor cells. Comparing clinicopathologic characteristics between tumors with low (<25%) and high (25% to 70%) TAM densities, primary tumors were larger in the high density group than in the low density group (2.0+/-0.1 vs. 1.5+/-0.1; P=0.009). CONCLUSION: TAMs were identified in primary PTC tumors with LN metastasis and higher TAM densities were related to larger tumor sizes, suggesting a tumorigenic role of TAMs in human PTCs.


Subject(s)
Carcinoma , Cytoplasm , Factor IX , Humans , Lymph Nodes , Macrophages , Neoplasm Metastasis , Prognosis , Thyroid Gland , Thyroid Neoplasms
18.
Journal of Gastric Cancer ; : 164-172, 2012.
Article in English | WPRIM | ID: wpr-11136

ABSTRACT

PURPOSE: The purpose of this study is to investigate the prognostic significance of tumor size for 5-year survival rate in patients with gastric cancer. MATERIALS AND METHODS: A total of 1,697 patients with gastric cancer, who underwent potentially curative gastrectomy, were evaluated. Patients were divided into 4 groups as follows, according to the median size of early and advanced gastric cancer, respectively: small early gastric cancer (tumor size 3 cm), small advanced gastric cancer (tumor size 6 cm). The prognostic value of tumor size for 5-year survival rate was investigated. RESULTS: In a univariate analysis, tumor size is a significant prognostic factor in advanced gastric cancer, but not in early gastric cancer. Multivariate analysis showed that tumor size is an independent prognostic factor for 5-year survival rate in advanced gastric cancer (P=0.003, hazard ratio=1.372, 95% confidence interval=1.115~1.690). When advanced gastric cancer is subdivided into 2 groups, according to serosa invasion: Group 1; serosa negative (T2 and T3, 7th AJCC), and Group 2; serosa positive (T4a and T4b, 7th AJCC), tumor size is an independent prognostic factor in Group 1 (P=0.011, hazard ratio=1.810, 95% confidence interval=1.149~2.852) and in Group 2 (P=0.033, hazard ratio=1.288, 95% confidence interval=1.020~1.627), respectively. CONCLUSIONS: Tumor size is an independent prognostic factor in advanced gastric cancer irrespective of the serosa invasion, but not in early gastric cancer.


Subject(s)
Gastrectomy , Humans , Multivariate Analysis , Prognosis , Serous Membrane , Stomach Neoplasms , Survival Rate
19.
Yonsei Medical Journal ; : 924-930, 2012.
Article in English | WPRIM | ID: wpr-228780

ABSTRACT

PURPOSE: We evaluated whether the clinicopathological factors of papillary thyroid microcarcinoma (PTMC), especially tumoe size, are associated with subcinical central lymph node metastasis. MATERIALS AND METHODS: A total of 160 patients diagnosed with PTMC who underwent total thyroidectomy with bilateral central lymph node dissection were enrolled in this study. All patients were clinically lymph node negative PTMC. Patients were divided into 2 groups according to the size of tumor (5 mm). Clinicopathologic risk factors for subclinical central lymph node metastasis were analyzed. RESULTS: Subclinical central lymph node metastasis was detected in 61 (38.1%). Patients with tumors 5 mm were independent predictors of subclinical central lymph node metastasis; age, multifocality, bilaterality, extrathyroidal extension, lymphvascular invasion and lymphocytic thyroiditis were not. CONCLUSION: In this study, male and tumor size >5 mm were two independent predictive factors for subclinical central lymph node metastasis in PTMC. These are easier factors to assess before surgery than other factors when planning the central lymph node dissection. However, further long-term follow-up studies are needed to confirm the prognostic significance of subclinical central lymph node metastasis in PTMC.


Subject(s)
Follow-Up Studies , Humans , Lymph Node Excision , Lymph Nodes , Male , Multivariate Analysis , Neoplasm Metastasis , Risk Factors , Thyroid Gland , Thyroidectomy , Thyroiditis, Autoimmune
20.
Clinical Endoscopy ; : 245-247, 2012.
Article in English | WPRIM | ID: wpr-216902

ABSTRACT

Endoscopic resection has been accepted as both minimally invasive and curative treatment modality for early gastric cancer (EGC). The widely accepted indication of endoscopic resection for EGC is small sized, differentiated mucosal cancer in which the risk of lymph node metastasis is negligible. Tumor size can be measured by conventional endoscopy, and chromoendoscopy, magnifying endoscopy, narrow band imaging, autofluorescence imaging can also be helpful for accurate estimation of tumor size. Pretreatment tumor histology can be assessed with endoscopic biopsy, and also be measured by confocal endomicroscopy (so called "virtual biopsy"). Although endoscopic ultrasonography may be helpful for the assessment of tumor depth in EGC, the accurate assessment of tumor depth can be performed by the typical findings in the conventional endoscopy, by which treatment modality can be decided according to the depth of tumor invasion.


Subject(s)
Biopsy , Endoscopy , Endosonography , Lymph Nodes , Narrow Band Imaging , Neoplasm Metastasis , Optical Imaging , Stomach Neoplasms
SELECTION OF CITATIONS
SEARCH DETAIL